Cormedix Inc CRMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $8.67
- Day Range
- $8.68–8.84
- 52-Week Range
- $6.13–17.43
- Bid/Ask
- $8.73 / $8.74
- Shares Outstanding
- 78.45M
- Market Cap
- $684.89M
- Volume/Avg
- 765,823 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 3.63
- Price/Sales
- 1.89
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 191
- Website
- https://www.cormedix.com
Valuation
|
Metric
|
CRMD
|
|---|---|
Price/Earnings (Normalized) | 3.63 |
Price/Book Value | 1.57 |
Price/Sales | 1.89 |
Price/Cash Flow | 3.46 |
Price/Earnings
CRMD
Financial Strength
|
Metric
|
CRMD
|
|---|---|
Quick Ratio | 2.59 |
Current Ratio | 2.98 |
Interest Coverage | — |
Quick Ratio
CRMD
Profitability
|
Metric
|
CRMD
|
|---|---|
Return on Assets (Normalized) | 36.87% |
Return on Equity (Normalized) | 66.39% |
Return on Invested Capital (Normalized) | 51.63% |
Return on Assets
CRMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Sbltrwxs | Bdlprwm | $116B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xmjqmhvr | Plxscb | $64B | |||
| argenx SE ADR
ARGX
| Xnpwpmfnc | Vpwc | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tcpkvlkfh | Dfbyb | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| Hrthgqyw | Jhc | $30B | |||
| Moderna Inc
MRNA
| Dngwpltd | Yjfj | $25B | |||
| Royalty Pharma PLC Class A
RPRX
| Xpltjkvr | Lqmcrp | $24B | |||
| BioNTech SE ADR
BNTX
| Dqqvsmf | Zscq | $23B | |||
| Incyte Corp
INCY
| Htbcwmnb | Qytyz | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Mnyrfxs | Mhbxh | $14B |
United States